Jump to content

The CHRYSALIS Study


KatieB

Recommended Posts

Trial ID: NCT02609776

Condition: Non-Small Cell Lung Cancer Intervention: Parallel Assignment Study Type: Interventional

Study Phase: I

Study Sponsor: Janssen Research & Development, LLC Trial Start Date: May 24, 2016

Trial End Date: November 1, 2023

Participant Goal: 460

Age Group: 18+ years of age Gender: All

Contact: JNJ.CT@sylogent.com

Study Summary: The CHRYSALIS Study is for adults with previously treated advanced non-small-cell lung cancer (NSCLC). The study is broken down into different parts and is specifically recruiting patients with NSCLC that have a documented primary MET Exon 14 skipping mutation. An investigational medication will be given to eligible participants to assess its the safety, tolerability, and anti-tumor activity.

You may be able to take part in the study if you:

·        Are 18 years or older

·        Have been diagnosed with metastatic or unresectable NSCLC with a documented primary MET Exon 14 skipping mutation

·        Must have received prior treatment or declined currently available treatment. There are no limits on lines of prior treatment nor on the type of prior treatment. Patients are eligible post- chemo and post-MET TKI(s).

 

Trial Eligibility Criteria:  https://clinicaltrials.gov/ct2/show/NCT02609776?term=61186372EDI1001&draw=2&rank=1

Locations:  https://clinicaltrials.gov/ct2/show/NCT02609776?term=61186372EDI1001&draw=2&rank=1

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
×
  • Create New...

Important Information

By using this site, you agree to our Terms of Use.